Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free GEHC Stock Alerts

GE HealthCare Technologies (GEHC) Financials

GE HealthCare Technologies logo
$70.26 +0.53 (+0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$70.17 -0.09 (-0.13%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for GE HealthCare Technologies

Annual Income Statements for GE HealthCare Technologies

This table shows GE HealthCare Technologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 2,247 1,916 1,385 1,993 2,084
Consolidated Net Income / (Loss)		 2,293 1,967 1,614 2,050 2,154
Net Income / (Loss) Continuing Operations		 2,275 1,949 1,618 2,050 2,154
Total Pre-Tax Income 		2,875 2,512 2,361 2,581 2,768
Total Operating Income		 2,795 2,522 2,435 2,625 2,763
Total Gross Profit		 7,174 7,179 7,922 8,205 8,248
Total Revenue		 17,585 18,341 19,552 19,672 20,625
Operating Revenue		 17,585 18,341 19,552 19,672 20,625
Total Cost of Revenue		 10,411 11,162 11,630 11,467 12,378
Operating Cost of Revenue		 10,411 11,162 11,630 11,467 12,378
Total Operating Expenses		 4,379 4,657 5,487 5,580 5,485
Selling, General & Admin Expense		 3,563 3,631 4,282 4,269 4,225
Research & Development Expense		 816 1,026 1,205 1,311 1,260
Total Other Income / (Expense), net		 80 -10 -74 -43 5.00
Interest Expense		 40 77 542 504 440
Other Income / (Expense), net		 120 67 468 461 445
Income Tax Expense		 600 563 743 531 614
Net Income / (Loss) Discontinued Operations		 18 18 -4.00 0.00 0.00
Preferred Stock Dividends Declared		 0.00 0.00 183 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 46 51 46 57 70
Basic Earnings per Share		 $4.95 $4.22 $3.05 $4.37 $4.56
Weighted Average Basic Shares Outstanding		 454M 454M 455M 456M 456M
Diluted Earnings per Share		 $4.95 $4.22 $3.03 $4.34 $4.55
Weighted Average Diluted Shares Outstanding		 454M 454M 458M 459M 458M
Weighted Average Basic & Diluted Shares Outstanding		 - - 455.36M 457.30M 455.75M
Cash Dividends to Common per Share		 - - $0.12 $0.13 $0.14

Quarterly Income Statements for GE HealthCare Technologies

This table shows GE HealthCare Technologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 403 374 428 470 721 564 486 446 588 389 561
Consolidated Net Income / (Loss)		 416 388 435 490 737 588 500 464 602 411 573
Net Income / (Loss) Continuing Operations		 416 388 435 490 737 588 500 464 602 411 574
Total Pre-Tax Income 		609 512 578 658 833 692 613 643 820 505 693
Total Operating Income		 689 540 608 676 801 629 654 653 827 515 739
Total Gross Profit		 2,156 1,902 2,002 2,026 2,275 2,012 1,985 1,990 2,261 1,977 2,180
Total Revenue		 5,206 4,650 4,839 4,863 5,320 4,777 5,007 5,143 5,698 5,131 5,295
Operating Revenue		 5,206 4,650 4,839 4,863 5,320 4,777 5,007 5,143 5,698 5,131 5,295
Total Cost of Revenue		 3,050 2,749 2,837 2,838 3,043 2,765 3,023 3,154 3,436 3,154 3,115
Operating Cost of Revenue		 3,050 2,749 2,837 2,838 3,043 2,765 3,023 3,154 3,436 3,154 3,115
Total Operating Expenses		 1,467 1,362 1,394 1,350 1,474 1,384 1,331 1,337 1,433 1,462 1,441
Selling, General & Admin Expense		 1,152 1,038 1,067 1,034 1,130 1,040 1,029 1,045 1,111 1,117 1,118
Research & Development Expense		 315 324 327 316 344 344 302 292 322 345 323
Total Other Income / (Expense), net		 -80 -28 -29 -19 33 63 -41 -10 -7.00 -9.00 -47
Interest Expense		 131 122 131 130 121 110 113 111 106 96 114
Other Income / (Expense), net		 51 94 102 111 154 173 72 101 99 87 67
Income Tax Expense		 193 124 143 168 96 104 113 179 218 94 119
Net Income / (Loss) Attributable to Noncontrolling Interest		 13 14 7.00 19 17 24 14 18 14 22 13
Basic Earnings per Share		 $0.89 $0.82 $0.94 $1.03 $1.58 $1.23 $1.06 $0.98 $1.29 $0.85 $1.24
Weighted Average Basic Shares Outstanding		 455M 456M 457M 457M 456M 457M 457M 456M 456M 456M 453M
Diluted Earnings per Share		 $0.89 $0.81 $0.93 $1.02 $1.58 $1.23 $1.06 $0.98 $1.28 $0.85 $1.24
Weighted Average Diluted Shares Outstanding		 458M 459M 459M 459M 459M 459M 458M 457M 458M 457M 454M
Weighted Average Basic & Diluted Shares Outstanding		 455.36M 456.47M 456.66M 456.87M 457.30M 457.88M 456.56M 455.52M 455.75M 454.89M 451.69M

Annual Cash Flow Statements for GE HealthCare Technologies

This table details how cash moves in and out of GE HealthCare Technologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -451 890 1,055 387 1,623
Net Cash From Operating Activities		 1,607 2,113 2,101 1,951 1,987
Net Cash From Continuing Operating Activities		 1,607 2,134 2,101 1,955 1,987
Net Income / (Loss) Continuing Operations		 2,275 1,949 1,618 2,050 2,154
Consolidated Net Income / (Loss)		 2,293 1,967 1,614 2,050 2,154
Net Income / (Loss) Discontinued Operations		 18 18 -4.00 0.00 0.00
Depreciation Expense		 225 228 248 268 287
Amortization Expense		 400 405 362 312 291
Non-Cash Adjustments To Reconcile Net Income		 45 -263 -306 -524 -387
Changes in Operating Assets and Liabilities, net		 -1,338 -185 178 -151 -357
Net Cash From Discontinued Operating Activities		 0.00 -21 0.00 -4.00 0.00
Net Cash From Investing Activities		 -1,761 -398 -558 -914 -1,047
Net Cash From Continuing Investing Activities		 -1,761 -398 -558 -914 -1,047
Purchase of Property, Plant & Equipment		 -248 -310 -387 -401 -482
Acquisitions		 -1,481 0.00 -147 -313 -378
Purchase of Investments		 - -59 -48 -40 -118
Sale of Property, Plant & Equipment		 15 4.00 1.00 0.00 0.00
Other Investing Activities, net		 -47 -33 23 -160 -69
Net Cash From Financing Activities		 -263 -822 -478 -573 617
Net Cash From Continuing Financing Activities		 -263 -822 -478 -572 618
Repayment of Debt		 -23 -95 -904 -1,452 -1,848
Repurchase of Common Equity		 0.00 0.00 -211 0.00 -200
Payment of Dividends		 0.00 0.00 -41 -55 -64
Issuance of Debt		 -2.00 8,207 1,994 995 2,735
Issuance of Common Equity		 - 0.00 34 33 37
Other Financing Activities, net		 -238 -8,934 -1,350 -93 -42
Effect of Exchange Rate Changes		 -34 -3.00 -10 -77 66
Cash Interest Paid		 21 0.00 570 550 522

Quarterly Cash Flow Statements for GE HealthCare Technologies

This table details how cash moves in and out of GE HealthCare Technologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 86 59 -547 1,554 -679 -416 1,289 264 486 -2,227 -180
Net Cash From Operating Activities		 1,050 419 -119 738 913 250 94 593 1,050 290 168
Net Cash From Continuing Operating Activities		 1,050 419 -121 744 913 250 95 592 1,050 288 171
Net Income / (Loss) Continuing Operations		 416 388 435 489 738 588 500 464 602 411 574
Consolidated Net Income / (Loss)		 416 388 435 489 738 588 500 464 602 411 574
Depreciation Expense		 60 68 69 66 65 66 72 75 74 78 76
Amortization Expense		 84 80 80 77 75 70 76 73 72 75 84
Non-Cash Adjustments To Reconcile Net Income		 -9.00 -105 -202 -91 -137 -230 -185 -14 42 -107 -95
Changes in Operating Assets and Liabilities, net		 499 -12 -503 203 171 -244 -368 -5.00 260 -169 -468
Net Cash From Investing Activities		 -88 -188 -349 -137 -240 -407 -223 -148 -269 -2,500 -115
Net Cash From Continuing Investing Activities		 -88 -188 -350 -137 -240 -407 -222 -149 -269 -2,501 -113
Purchase of Property, Plant & Equipment		 -94 -145 -64 -90 -102 -152 -86 -110 -134 -178 -100
Acquisitions		 - 0.00 -259 - -54 -269 -10 - -99 -2,297 4.00
Purchase of Investments		 -27 -19 - - -7.00 -20 -8.00 -54 -36 -13 -6.00
Other Investing Activities, net		 33 -24 -27 -14 -77 34 -118 15 - -13 -11
Net Cash From Financing Activities		 -900 -153 -57 914 -1,277 -286 1,361 -165 -293 21 -236
Net Cash From Continuing Financing Activities		 -900 -153 -57 914 -1,276 -286 1,360 -165 -291 21 -237
Repayment of Debt		 -871 -146 -42 -7.00 -1,262 -263 -13 -45 -1,527 -1,005 -19
Repurchase of Common Equity		 - - - - - 0.00 - -100 - -100 -200
Payment of Dividends		 -13 -14 -14 -13 -14 -16 -16 -16 -16 -16 -16
Other Financing Activities, net		 -2.00 -11 - -90 -3.00 -28 -5.00 -8.00 -1.00 -19 -2.00
Effect of Exchange Rate Changes		 24 -19 -22 39 -75 27 57 -16 -2.00 -37 2.00
Cash Interest Paid		 252 55 219 65 211 78 182 67 195 87 193

Annual Balance Sheets for GE HealthCare Technologies

This table presents GE HealthCare Technologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 27,539 32,454 33,089 36,906
Total Current Assets		 8,318 9,410 9,901 12,501
Cash & Equivalents		 1,445 2,504 2,889 4,512
Accounts Receivable		 3,312 3,557 3,566 3,955
Inventories, net		 2,155 1,960 1,939 2,234
Other Current Assets		 1,406 1,389 1,506 1,799
Plant, Property, & Equipment, net		 2,314 2,500 2,550 3,092
Total Noncurrent Assets		 16,907 20,544 20,638 21,315
Goodwill		 12,813 12,936 13,136 13,489
Intangible Assets		 1,520 1,253 1,078 1,130
Noncurrent Deferred & Refundable Income Taxes		 1,550 4,474 4,474 4,491
Other Noncurrent Operating Assets		 1,024 1,881 1,950 2,205
Total Liabilities & Shareholders' Equity		 27,539 32,454 33,089 36,906
Total Liabilities		 17,947 25,144 24,437 26,307
Total Current Liabilities		 7,191 8,981 9,553 9,105
Short-Term Debt		 15 1,006 1,502 508
Accounts Payable		 2,944 2,947 3,035 3,250
Current Employee Benefit Liabilities		 - 1,518 1,521 1,666
Other Current Liabilities		 4,232 3,510 3,495 3,682
Total Noncurrent Liabilities		 10,756 16,163 14,884 17,202
Long-Term Debt		 8,234 8,436 7,449 9,495
Noncurrent Deferred & Payable Income Tax Liabilities		 370 68 56 193
Noncurrent Employee Benefit Liabilities		 549 5,782 5,583 5,453
Other Noncurrent Operating Liabilities		 1,603 1,877 1,796 2,061
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 230 165 188 209
Total Equity & Noncontrolling Interests		 9,362 7,145 8,464 10,390
Total Preferred & Common Equity		 9,357 7,133 8,446 10,379
Total Common Equity		 9,357 7,133 8,446 10,380
Common Stock		 0.00 6,498 6,588 6,712
Retained Earnings		 0.00 1,326 3,262 5,281
Treasury Stock		 - 0.00 -25 -225
Accumulated Other Comprehensive Income / (Loss)		 -1,878 -691 -1,379 -1,388
Noncontrolling Interest		 5.00 12 18 11

Quarterly Balance Sheets for GE HealthCare Technologies

This table presents GE HealthCare Technologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 32,382 32,454 32,208 31,852 33,855 33,089 33,586 35,500 36,127 37,125 37,246
Total Current Assets		 9,468 9,410 9,373 8,806 10,638 9,901 9,735 11,308 11,893 10,426 10,497
Cash & Equivalents		 2,418 2,504 2,563 2,015 3,568 2,889 2,473 3,763 4,027 2,285 2,105
Accounts Receivable		 3,400 3,557 3,344 3,354 3,424 3,569 3,572 3,562 3,734 3,786 3,881
Inventories, net		 2,128 1,960 1,989 2,023 2,124 1,939 2,158 2,283 2,304 2,353 2,483
Other Current Assets		 1,522 1,389 1,478 1,414 1,522 1,503 1,532 1,700 1,827 2,001 2,028
Plant, Property, & Equipment, net		 2,355 2,500 2,445 2,458 2,539 2,550 2,851 2,962 3,010 3,095 3,146
Total Noncurrent Assets		 20,559 20,544 20,392 20,589 20,677 20,638 20,999 21,230 21,224 23,605 23,602
Goodwill		 12,914 12,936 12,927 13,116 13,138 13,136 13,373 13,417 13,441 15,060 15,095
Intangible Assets		 1,332 1,253 1,174 1,195 1,132 1,078 1,238 1,220 1,163 1,908 1,894
Noncurrent Deferred & Refundable Income Taxes		 4,277 4,474 4,413 4,365 4,309 4,474 4,462 4,517 4,468 4,383 4,359
Other Noncurrent Operating Assets		 2,036 1,881 1,878 1,913 2,098 1,950 1,926 2,076 2,152 2,254 2,254
Total Liabilities & Shareholders' Equity		 32,382 32,454 32,208 31,852 33,855 33,089 33,586 35,500 36,127 37,125 37,246
Total Liabilities		 25,079 25,144 24,609 23,858 25,343 24,437 24,168 25,548 25,907 26,227 26,027
Total Current Liabilities		 7,565 8,981 8,859 8,318 8,670 9,553 9,969 9,748 10,073 8,529 8,302
Short-Term Debt		 7.00 1,006 1,008 1,007 1,007 1,502 2,002 2,005 2,005 7.00 2.00
Accounts Payable		 2,774 2,947 2,931 2,824 2,911 3,022 3,152 2,975 2,987 3,410 3,231
Current Employee Benefit Liabilities		 - 1,518 - 1,235 1,422 1,521 1,343 1,364 1,542 1,418 1,439
Other Current Liabilities		 4,784 3,510 4,920 3,251 3,331 3,508 3,472 3,405 3,538 3,695 3,629
Total Noncurrent Liabilities		 17,514 16,163 15,751 15,539 16,673 14,884 14,199 15,799 15,835 17,698 17,725
Long-Term Debt		 10,253 8,436 8,247 8,233 9,306 7,449 6,757 8,270 8,277 10,127 10,091
Noncurrent Deferred & Payable Income Tax Liabilities		 62 68 68 55 59 56 159 173 171 256 315
Noncurrent Employee Benefit Liabilities		 5,373 5,782 5,625 5,455 5,388 5,583 5,443 5,351 5,287 5,300 5,186
Other Noncurrent Operating Liabilities		 1,826 1,877 1,811 1,796 1,920 1,796 1,840 2,005 2,100 2,015 2,133
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 161 165 177 177 177 188 211 220 204 218 229
Total Equity & Noncontrolling Interests		 7,142 7,145 7,423 7,817 8,335 8,464 9,207 9,733 10,016 10,680 10,989
Total Preferred & Common Equity		 7,131 7,133 7,408 7,801 8,317 8,446 9,187 9,712 9,993 10,668 10,975
Total Common Equity		 7,131 7,133 7,409 7,801 8,318 8,446 9,188 9,713 9,994 10,669 10,975
Common Stock		 6,474 6,498 6,509 6,545 6,556 6,588 6,602 6,633 6,666 6,738 6,781
Retained Earnings		 937 1,326 1,687 2,101 2,558 3,262 3,810 4,295 4,709 5,654 6,199
Treasury Stock		 - 0.00 - - -25 -25 -25 -125 -225 -325 -525
Accumulated Other Comprehensive Income / (Loss)		 -280 -691 -787 -845 -771 -1,379 -1,199 -1,090 -1,156 -1,398 -1,480
Noncontrolling Interest		 11 12 14 16 18 18 20 21 23 12 14

Annual Metrics And Ratios for GE HealthCare Technologies

This table displays calculated financial ratios and metrics derived from GE HealthCare Technologies' official financial filings.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 4.30% 6.60% 0.61% 4.84%
EBITDA Growth		 0.00% -8.98% 9.03% 4.36% 3.27%
EBIT Growth		 0.00% -11.18% 12.13% 6.30% 3.95%
NOPAT Growth		 0.00% -11.53% -14.72% 24.94% 3.13%
Net Income Growth		 0.00% -14.22% -17.95% 27.01% 5.07%
EPS Growth		 0.00% -14.75% -28.20% 43.23% 4.84%
Operating Cash Flow Growth		 0.00% 31.49% -0.57% -7.14% 1.85%
Free Cash Flow Firm Growth		 0.00% 0.00% 126.43% -57.56% -52.28%
Invested Capital Growth		 0.00% 0.00% -13.10% 3.26% 9.36%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.58% 1.87%
EBITDA Q/Q Growth		 0.00% 0.00% 463.88% 6.11% -0.60%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 7.49% -0.90%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 13.10% -4.56%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 18.57% -5.90%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 18.90% -6.19%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.38% -6.56% 7.41%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -6.55% -25.22%
Invested Capital Q/Q Growth		 0.00% 0.00% -5.92% -3.55% -2.33%
Profitability Metrics		 - - - - -
Gross Margin		 40.80% 39.14% 40.52% 41.71% 39.99%
EBITDA Margin		 20.13% 17.57% 17.97% 18.64% 18.36%
Operating Margin		 15.89% 13.75% 12.45% 13.34% 13.40%
EBIT Margin		 16.58% 14.12% 14.85% 15.69% 15.55%
Profit (Net Income) Margin		 13.04% 10.72% 8.25% 10.42% 10.44%
Tax Burden Percent		 79.76% 78.30% 68.36% 79.43% 77.82%
Interest Burden Percent		 98.63% 97.03% 81.33% 83.64% 86.28%
Effective Tax Rate		 20.87% 22.41% 31.47% 20.57% 22.18%
Return on Invested Capital (ROIC)		 0.00% 23.87% 10.89% 14.40% 13.96%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 24.17% 10.09% 13.86% 14.03%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 17.14% 8.21% 11.29% 8.42%
Return on Equity (ROE)		 0.00% 41.01% 19.10% 25.69% 22.38%
Cash Return on Invested Capital (CROIC)		 0.00% -176.13% 24.91% 11.19% 5.02%
Operating Return on Assets (OROA)		 0.00% 9.40% 9.68% 9.42% 9.17%
Return on Assets (ROA)		 0.00% 7.14% 5.38% 6.26% 6.15%
Return on Common Equity (ROCE)		 0.00% 40.01% 18.63% 25.07% 21.88%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 21.02% 22.63% 24.27% 0.00%
Net Operating Profit after Tax (NOPAT)		 2,212 1,957 1,669 2,085 2,150
NOPAT Margin		 12.58% 10.67% 8.53% 10.60% 10.42%
Net Nonoperating Expense Percent (NNEP)		 0.00% -0.30% 0.80% 0.54% -0.07%
Return On Investment Capital (ROIC_SIMPLE)		 - 11.11% 10.06% 11.97% 10.54%
Cost of Revenue to Revenue		 59.20% 60.86% 59.48% 58.29% 60.01%
SG&A Expenses to Revenue		 20.26% 19.80% 21.90% 21.70% 20.48%
R&D to Revenue		 4.64% 5.59% 6.16% 6.66% 6.11%
Operating Expenses to Revenue		 24.90% 25.39% 28.06% 28.37% 26.59%
Earnings before Interest and Taxes (EBIT)		 2,915 2,589 2,903 3,086 3,208
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3,540 3,222 3,513 3,666 3,786
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 0.00 4.91 4.20 3.59
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 1.79 1.80 1.80
Price to Earnings (P/E)		 0.00 0.00 25.29 17.80 17.86
Dividend Yield		 0.00% 0.00% 0.12% 0.15% 0.17%
Earnings Yield		 0.00% 0.00% 3.95% 5.62% 5.60%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 2.96 2.84 2.67
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 2.16 2.12 2.08
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 12.00 11.39 11.34
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 14.52 13.53 13.38
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 25.26 20.02 19.97
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 20.06 21.39 21.60
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 11.04 25.77 55.53
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.86 1.29 1.03 0.94
Long-Term Debt to Equity		 0.00 0.86 1.15 0.86 0.90
Financial Leverage		 0.00 0.71 0.81 0.81 0.60
Leverage Ratio		 0.00 2.87 3.55 4.11 3.64
Compound Leverage Factor		 0.00 2.79 2.89 3.43 3.14
Debt to Total Capital		 0.00% 46.24% 56.36% 50.85% 48.55%
Short-Term Debt to Total Capital		 0.00% 0.08% 6.01% 8.53% 2.47%
Long-Term Debt to Total Capital		 0.00% 46.15% 50.36% 42.32% 46.09%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 1.32% 1.06% 1.17% 1.07%
Common Equity to Total Capital		 0.00% 52.45% 42.58% 47.98% 50.38%
Debt to EBITDA		 0.00 2.56 2.69 2.44 2.64
Net Debt to EBITDA		 0.00 2.11 1.98 1.65 1.45
Long-Term Debt to EBITDA		 0.00 2.56 2.40 2.03 2.51
Debt to NOPAT		 0.00 4.22 5.66 4.29 4.65
Net Debt to NOPAT		 0.00 3.48 4.16 2.91 2.55
Long-Term Debt to NOPAT		 0.00 4.21 5.06 3.57 4.42
Altman Z-Score		 0.00 0.00 1.81 1.92 2.01
Noncontrolling Interest Sharing Ratio		 0.00% 2.45% 2.44% 2.40% 2.21%
Liquidity Ratios		 - - - - -
Current Ratio		 0.00 1.16 1.05 1.04 1.37
Quick Ratio		 0.00 0.66 0.67 0.68 0.93
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -14,439 3,817 1,620 773
Operating Cash Flow to CapEx		 689.70% 690.52% 544.30% 486.53% 412.24%
Free Cash Flow to Firm to Interest Expense		 0.00 -187.52 7.04 3.21 1.76
Operating Cash Flow to Interest Expense		 40.18 27.44 3.88 3.87 4.52
Operating Cash Flow Less CapEx to Interest Expense		 34.35 23.47 3.16 3.08 3.42
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.67 0.65 0.60 0.59
Accounts Receivable Turnover		 0.00 5.54 5.69 5.52 5.48
Inventory Turnover		 0.00 5.18 5.65 5.88 5.93
Fixed Asset Turnover		 0.00 7.93 8.12 7.79 7.31
Accounts Payable Turnover		 0.00 3.79 3.95 3.84 3.94
Days Sales Outstanding (DSO)		 0.00 65.91 64.12 66.11 66.55
Days Inventory Outstanding (DIO)		 0.00 70.47 64.57 62.05 61.53
Days Payable Outstanding (DPO)		 0.00 96.27 92.44 95.00 92.67
Cash Conversion Cycle (CCC)		 0.00 40.11 36.25 33.16 35.41
Capital & Investment Metrics		 - - - - -
Invested Capital		 0.00 16,396 14,248 14,713 16,090
Invested Capital Turnover		 0.00 2.24 1.28 1.36 1.34
Increase / (Decrease) in Invested Capital		 0.00 16,396 -2,148 465 1,377
Enterprise Value (EV)		 0.00 0.00 42,147 41,741 42,927
Market Capitalization		 0.00 0.00 35,032 35,473 37,216
Book Value per Share		 $0.00 $20.61 $15.67 $18.49 $22.79
Tangible Book Value per Share		 $0.00 ($10.96) ($15.50) ($12.63) ($9.31)
Total Capital		 0.00 17,841 16,752 17,603 20,602
Total Debt		 0.00 8,249 9,442 8,951 10,003
Total Long-Term Debt		 0.00 8,234 8,436 7,449 9,495
Net Debt		 0.00 6,804 6,938 6,062 5,491
Capital Expenditures (CapEx)		 233 306 386 401 482
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -303 -1,069 -1,039 -608
Debt-free Net Working Capital (DFNWC)		 0.00 1,142 1,435 1,850 3,904
Net Working Capital (NWC)		 0.00 1,127 429 348 3,396
Net Nonoperating Expense (NNE)		 -81 -10 55 35 -3.89
Net Nonoperating Obligations (NNO)		 0.00 6,804 6,938 6,061 5,491
Total Depreciation and Amortization (D&A)		 625 633 610 580 578
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -1.65% -5.47% -5.28% -2.95%
Debt-free Net Working Capital to Revenue		 0.00% 6.23% 7.34% 9.40% 18.93%
Net Working Capital to Revenue		 0.00% 6.14% 2.19% 1.77% 16.47%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $3.05 $4.37 $4.56
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 455M 456M 456M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $3.03 $4.34 $4.55
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 458M 459M 458M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 455.36M 457.30M 455.75M
Normalized Net Operating Profit after Tax (NOPAT)		 2,212 1,957 1,669 2,085 2,150
Normalized NOPAT Margin		 12.58% 10.67% 8.53% 10.60% 10.42%
Pre Tax Income Margin		 16.35% 13.70% 12.08% 13.12% 13.42%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 72.88 33.62 5.36 6.12 7.29
NOPAT to Interest Expense		 55.29 25.41 3.08 4.14 4.89
EBIT Less CapEx to Interest Expense		 67.05 29.65 4.64 5.33 6.20
NOPAT Less CapEx to Interest Expense		 49.47 21.44 2.37 3.34 3.79
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 2.54% 2.68% 2.97%
Augmented Payout Ratio		 0.00% 0.00% 15.61% 2.68% 12.26%

Quarterly Metrics And Ratios for GE HealthCare Technologies

This table displays calculated financial ratios and metrics derived from GE HealthCare Technologies' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 455,749,767.00 454,891,786.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 455,749,767.00 454,891,786.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.85 1.23
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -1.21% 0.46% 0.85% 2.19% 2.73% 3.47% 5.76% 7.11% 7.41% 5.75%
EBITDA Growth		 463.06% -6.79% -0.46% 0.32% 23.87% 19.95% 1.75% -3.01% -2.10% -19.51% 10.53%
EBIT Growth		 0.00% -7.04% 0.42% 1.68% 29.05% 26.50% 2.25% -4.19% -3.04% -24.94% 11.02%
NOPAT Growth		 0.00% 4.36% 5.68% 34.43% 50.58% 30.61% 16.58% -6.39% -14.33% -21.58% 14.75%
Net Income Growth		 0.00% 1.31% 0.46% 28.27% 77.16% 51.55% 14.94% -5.31% -18.32% -30.10% 14.60%
EPS Growth		 0.00% 97.56% 2.20% 24.39% 77.53% 51.85% 13.98% -3.92% -18.99% -30.89% 16.98%
Operating Cash Flow Growth		 0.77% -10.47% -77.61% 13.54% -13.05% -40.33% 178.99% -19.65% 15.01% 16.00% 78.72%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 102.66% -90.69% 93.69% 95.20% -290.08% -415.92% -199.69% -200.74%
Invested Capital Growth		 -13.10% 0.00% 0.00% 0.73% 3.26% 9.87% 8.16% 7.99% 9.36% 19.38% 16.66%
Revenue Q/Q Growth		 7.96% 0.00% 4.06% 0.50% 9.40% -10.21% 4.81% 2.72% 10.79% -9.95% 3.20%
EBITDA Q/Q Growth		 -4.64% 443.06% 9.85% 8.27% 17.74% -14.34% -6.82% 3.20% 18.85% -29.57% 27.95%
EBIT Q/Q Growth		 -4.39% 0.00% 11.99% 10.85% 21.35% -16.02% -9.48% 3.86% 22.81% -34.99% 33.89%
NOPAT Q/Q Growth		 25.68% 0.00% 11.82% 10.02% 40.78% -24.58% -0.19% -11.67% 28.85% -30.97% 46.04%
Net Income Q/Q Growth		 8.90% 0.00% 12.11% 12.64% 50.41% -20.22% -14.97% -7.20% 29.74% -31.73% 39.42%
EPS Q/Q Growth		 8.54% 0.00% 14.81% 9.68% 54.90% -22.15% -13.82% -7.55% 30.61% -33.59% 45.88%
Operating Cash Flow Q/Q Growth		 61.54% -60.10% -128.40% 720.17% 23.71% -72.62% -62.40% 530.85% 77.07% -72.38% -42.07%
Free Cash Flow Firm Q/Q Growth		 117.73% -746.36% -6.34% 102.66% -38.06% -459.28% 19.07% -5.54% -2.95% -240.82% 18.79%
Invested Capital Q/Q Growth		 -5.92% 0.32% 6.50% 0.22% -3.55% 6.73% 4.85% 0.06% -2.33% 16.51% 2.46%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 41.41% 40.90% 41.37% 41.66% 42.76% 42.12% 39.64% 38.69% 39.68% 38.53% 41.17%
EBITDA Margin		 16.98% 16.82% 17.75% 19.12% 20.58% 19.64% 17.46% 17.54% 18.81% 14.71% 18.24%
Operating Margin		 13.23% 11.61% 12.56% 13.90% 15.06% 13.17% 13.06% 12.70% 14.51% 10.04% 13.96%
EBIT Margin		 14.21% 13.63% 14.67% 16.18% 17.95% 16.79% 14.50% 14.66% 16.25% 11.73% 15.22%
Profit (Net Income) Margin		 7.99% 8.34% 8.99% 10.08% 13.85% 12.31% 9.99% 9.02% 10.57% 8.01% 10.82%
Tax Burden Percent		 68.31% 75.78% 75.26% 74.47% 88.48% 84.97% 81.57% 72.16% 73.41% 81.39% 82.68%
Interest Burden Percent		 82.30% 80.76% 81.41% 83.61% 87.23% 86.28% 84.44% 85.28% 88.55% 83.89% 85.98%
Effective Tax Rate		 31.69% 24.22% 24.74% 25.53% 11.52% 15.03% 18.43% 27.84% 26.59% 18.61% 17.17%
Return on Invested Capital (ROIC)		 11.54% 24.01% 24.25% 13.32% 18.10% 14.77% 13.43% 11.69% 14.27% 9.95% 13.78%
ROIC Less NNEP Spread (ROIC-NNEP)		 10.74% 23.37% 23.62% 13.14% 18.53% 15.59% 12.94% 11.58% 14.18% 9.83% 13.24%
Return on Net Nonoperating Assets (RNNOA)		 8.73% 20.58% 21.36% 12.11% 15.09% 11.89% 9.91% 8.04% 8.51% 6.84% 9.07%
Return on Equity (ROE)		 20.27% 44.59% 45.61% 25.43% 33.19% 26.66% 23.33% 19.73% 22.78% 16.79% 22.86%
Cash Return on Invested Capital (CROIC)		 24.91% -176.42% -177.56% 11.40% 11.19% 5.35% 6.58% 6.52% 5.02% -5.89% -3.56%
Operating Return on Assets (OROA)		 9.27% 16.51% 17.98% 9.56% 10.78% 10.10% 8.60% 8.48% 9.58% 6.96% 8.90%
Return on Assets (ROA)		 5.21% 10.10% 11.02% 5.95% 8.32% 7.41% 5.92% 5.22% 6.23% 4.75% 6.33%
Return on Common Equity (ROCE)		 19.78% 43.47% 44.51% 24.85% 32.39% 26.00% 22.77% 19.29% 22.28% 16.41% 22.33%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 21.85% 20.78% 20.79% 0.00% 24.49% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 471 409 458 503 709 534 533 471 607 419 612
NOPAT Margin		 9.04% 8.80% 9.46% 10.35% 13.32% 11.19% 10.65% 9.16% 10.66% 8.17% 11.56%
Net Nonoperating Expense Percent (NNEP)		 0.80% 0.63% 0.62% 0.18% -0.44% -0.83% 0.49% 0.11% 0.09% 0.12% 0.54%
Return On Investment Capital (ROIC_SIMPLE)		 2.84% - - - 4.07% 2.97% 2.67% 2.32% 2.98% 2.01% 2.90%
Cost of Revenue to Revenue		 58.59% 59.12% 58.63% 58.36% 57.20% 57.88% 60.38% 61.33% 60.30% 61.47% 58.83%
SG&A Expenses to Revenue		 22.13% 22.32% 22.05% 21.26% 21.24% 21.77% 20.55% 20.32% 19.50% 21.77% 21.11%
R&D to Revenue		 6.05% 6.97% 6.76% 6.50% 6.47% 7.20% 6.03% 5.68% 5.65% 6.72% 6.10%
Operating Expenses to Revenue		 28.18% 29.29% 28.81% 27.76% 27.71% 28.97% 26.58% 26.00% 25.15% 28.49% 27.21%
Earnings before Interest and Taxes (EBIT)		 740 634 710 787 955 802 726 754 926 602 806
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 884 782 859 930 1,095 938 874 902 1,072 755 966
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.91 5.57 4.53 5.12 4.20 3.99 3.46 3.41 3.59 3.03 2.65
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1.79 2.12 1.81 2.18 1.80 1.85 1.68 1.68 1.80 1.54 1.37
Price to Earnings (P/E)		 25.29 26.28 22.38 25.43 17.80 16.77 15.00 15.37 17.86 16.92 14.64
Dividend Yield		 0.12% 0.13% 0.19% 0.13% 0.15% 0.16% 0.18% 0.18% 0.17% 0.20% 0.22%
Earnings Yield		 3.95% 3.81% 4.47% 3.93% 5.62% 5.96% 6.67% 6.51% 5.60% 5.91% 6.83%
Enterprise Value to Invested Capital (EV/IC)		 2.96 3.37 2.81 3.25 2.84 2.75 2.45 2.46 2.67 2.15 1.94
Enterprise Value to Revenue (EV/Rev)		 2.16 2.47 2.19 2.53 2.12 2.18 2.02 2.00 2.08 1.92 1.75
Enterprise Value to EBITDA (EV/EBITDA)		 12.00 13.93 12.39 14.33 11.39 11.29 10.52 10.65 11.34 11.21 10.09
Enterprise Value to EBIT (EV/EBIT)		 14.52 16.86 14.97 17.25 13.53 13.26 12.34 12.53 13.38 13.42 12.07
Enterprise Value to NOPAT (EV/NOPAT)		 25.26 28.57 25.05 26.87 20.02 19.50 17.66 18.00 19.97 19.90 17.69
Enterprise Value to Operating Cash Flow (EV/OCF)		 20.06 23.46 21.39 23.72 21.39 24.21 20.23 21.92 21.60 19.92 17.74
Enterprise Value to Free Cash Flow (EV/FCFF)		 11.04 0.00 0.00 28.57 25.77 53.80 38.69 39.23 55.53 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.29 1.22 1.16 1.21 1.03 0.93 1.03 1.01 0.94 0.93 0.90
Long-Term Debt to Equity		 1.15 1.09 1.03 1.09 0.86 0.72 0.83 0.81 0.90 0.93 0.90
Financial Leverage		 0.81 0.88 0.90 0.92 0.81 0.76 0.77 0.69 0.60 0.70 0.68
Leverage Ratio		 3.55 4.24 3.98 4.19 4.11 3.87 3.75 3.74 3.64 3.48 3.44
Compound Leverage Factor		 2.92 3.42 3.24 3.50 3.58 3.34 3.17 3.19 3.22 2.92 2.95
Debt to Total Capital		 56.36% 54.91% 53.61% 54.78% 50.85% 48.19% 50.80% 50.15% 48.55% 48.18% 47.36%
Short-Term Debt to Total Capital		 6.01% 5.98% 5.84% 5.35% 8.53% 11.01% 9.91% 9.78% 2.47% 0.03% 0.01%
Long-Term Debt to Total Capital		 50.36% 48.93% 47.77% 49.43% 42.32% 37.17% 40.88% 40.37% 46.09% 48.15% 47.35%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 1.06% 1.13% 1.12% 1.04% 1.17% 1.27% 1.19% 1.11% 1.07% 1.09% 1.14%
Common Equity to Total Capital		 42.58% 43.96% 45.27% 44.19% 47.98% 50.55% 48.02% 48.75% 50.38% 50.73% 51.50%
Debt to EBITDA		 2.69 2.68 2.68 2.98 2.44 2.29 2.68 2.70 2.64 2.81 2.73
Net Debt to EBITDA		 1.98 1.94 2.09 1.95 1.65 1.64 1.70 1.64 1.45 2.18 2.16
Long-Term Debt to EBITDA		 2.40 2.39 2.39 2.69 2.03 1.77 2.16 2.17 2.51 2.81 2.73
Debt to NOPAT		 5.66 5.49 5.41 5.59 4.29 3.96 4.50 4.56 4.65 4.99 4.79
Net Debt to NOPAT		 4.16 3.97 4.23 3.66 2.91 2.84 2.85 2.78 2.55 3.87 3.79
Long-Term Debt to NOPAT		 5.06 4.89 4.82 5.05 3.57 3.06 3.62 3.67 4.42 4.99 4.79
Altman Z-Score		 1.59 1.77 1.69 1.84 1.71 1.73 1.64 1.66 1.80 1.63 1.62
Noncontrolling Interest Sharing Ratio		 2.44% 2.51% 2.41% 2.31% 2.40% 2.47% 2.41% 2.24% 2.21% 2.26% 2.28%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.05 1.06 1.06 1.23 1.04 0.98 1.16 1.18 1.37 1.22 1.26
Quick Ratio		 0.67 0.67 0.65 0.81 0.68 0.61 0.75 0.77 0.93 0.71 0.72
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 2,619 -13,884 -14,764 393 244 -876 -709 -748 -770 -2,624 -2,131
Operating Cash Flow to CapEx		 1,117.02% 288.97% -185.94% 820.00% 895.10% 164.47% 109.30% 539.09% 783.58% 162.92% 168.00%
Free Cash Flow to Firm to Interest Expense		 19.99 -113.80 -112.71 3.03 2.01 -7.96 -6.27 -6.74 -7.26 -27.33 -18.69
Operating Cash Flow to Interest Expense		 8.02 3.43 -0.91 5.68 7.55 2.27 0.83 5.34 9.91 3.02 1.47
Operating Cash Flow Less CapEx to Interest Expense		 7.30 2.25 -1.40 4.98 6.70 0.89 0.07 4.35 8.64 1.17 0.60
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.65 1.21 1.23 0.59 0.60 0.60 0.59 0.58 0.59 0.59 0.58
Accounts Receivable Turnover		 5.69 0.00 0.00 5.73 5.52 5.73 5.77 5.66 5.48 5.70 5.71
Inventory Turnover		 5.65 0.00 0.00 5.40 5.88 5.54 5.42 5.41 5.93 5.66 5.40
Fixed Asset Turnover		 8.12 0.00 0.00 7.99 7.79 7.48 7.37 7.30 7.31 7.06 6.96
Accounts Payable Turnover		 3.95 0.00 0.00 4.04 3.84 3.78 4.02 4.06 3.94 3.89 4.14
Days Sales Outstanding (DSO)		 64.12 0.00 0.00 63.68 66.11 63.75 63.21 64.52 66.55 64.01 63.87
Days Inventory Outstanding (DIO)		 64.57 0.00 0.00 67.63 62.05 65.91 67.34 67.43 61.53 64.48 67.64
Days Payable Outstanding (DPO)		 92.44 0.00 0.00 90.42 95.00 96.68 90.69 89.81 92.67 93.80 88.08
Cash Conversion Cycle (CCC)		 36.25 0.00 0.00 40.88 33.16 32.98 39.86 42.14 35.41 34.69 43.43
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 14,248 14,293 15,222 15,255 14,713 15,703 16,464 16,474 16,090 18,746 19,207
Invested Capital Turnover		 1.28 2.73 2.56 1.29 1.36 1.32 1.26 1.28 1.34 1.22 1.19
Increase / (Decrease) in Invested Capital		 -2,148 14,293 15,222 110 465 1,410 1,242 1,219 1,377 3,043 2,743
Enterprise Value (EV)		 42,147 48,135 42,775 49,527 41,741 43,134 40,360 40,556 42,927 40,374 37,270
Market Capitalization		 35,032 41,252 35,357 42,587 35,473 36,617 33,607 34,074 37,216 32,295 29,039
Book Value per Share		 $15.67 $16.25 $17.09 $18.21 $18.49 $20.09 $21.21 $21.89 $22.79 $23.41 $24.13
Tangible Book Value per Share		 ($15.50) ($14.68) ($14.26) ($13.03) ($12.63) ($11.86) ($10.75) ($10.10) ($9.31) ($13.82) ($13.22)
Total Capital		 16,752 16,855 17,234 18,825 17,603 18,177 20,228 20,502 20,602 21,032 21,311
Total Debt		 9,442 9,255 9,240 10,313 8,951 8,759 10,275 10,282 10,003 10,134 10,093
Total Long-Term Debt		 8,436 8,247 8,233 9,306 7,449 6,757 8,270 8,277 9,495 10,127 10,091
Net Debt		 6,938 6,692 7,225 6,745 6,062 6,286 6,512 6,255 5,491 7,849 7,988
Capital Expenditures (CapEx)		 94 145 64 90 102 152 86 110 134 178 100
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1,069 -1,041 -520 -593 -1,039 -705 -198 -202 -608 -381 92
Debt-free Net Working Capital (DFNWC)		 1,435 1,522 1,495 2,975 1,850 1,768 3,565 3,825 3,904 1,904 2,197
Net Working Capital (NWC)		 429 514 488 1,968 348 -234 1,560 1,820 3,396 1,897 2,195
Net Nonoperating Expense (NNE)		 55 21 23 13 -28 -54 33 7.22 5.14 8.14 39
Net Nonoperating Obligations (NNO)		 6,938 6,693 7,228 6,743 6,061 6,285 6,511 6,254 5,491 7,848 7,989
Total Depreciation and Amortization (D&A)		 144 148 149 143 140 136 148 148 146 153 160
Debt-free, Cash-free Net Working Capital to Revenue		 -5.47% -5.34% -2.66% -3.03% -5.28% -3.56% -0.99% -1.00% -2.95% -1.82% 0.43%
Debt-free Net Working Capital to Revenue		 7.34% 7.81% 7.66% 15.21% 9.40% 8.93% 17.85% 18.89% 18.93% 9.08% 10.33%
Net Working Capital to Revenue		 2.19% 2.64% 2.50% 10.06% 1.77% -1.18% 7.81% 8.99% 16.47% 9.04% 10.32%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.89 $0.82 $0.94 $1.03 $1.58 $1.23 $1.06 $0.98 $1.29 $0.85 $1.24
Adjusted Weighted Average Basic Shares Outstanding		 455M 456M 457M 457M 456M 457M 457M 456M 456M 456M 453M
Adjusted Diluted Earnings per Share		 $0.89 $0.81 $0.93 $1.02 $1.58 $1.23 $1.06 $0.98 $1.28 $0.85 $1.24
Adjusted Weighted Average Diluted Shares Outstanding		 458M 459M 459M 459M 459M 459M 458M 457M 458M 457M 454M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 455.36M 456.47M 456.66M 456.87M 457.30M 457.88M 456.56M 455.52M 455.75M 454.89M 451.69M
Normalized Net Operating Profit after Tax (NOPAT)		 471 409 458 503 709 534 533 471 607 419 612
Normalized NOPAT Margin		 9.04% 8.80% 9.46% 10.35% 13.32% 11.19% 10.65% 9.16% 10.66% 8.17% 11.56%
Pre Tax Income Margin		 11.70% 11.01% 11.94% 13.53% 15.66% 14.49% 12.24% 12.50% 14.39% 9.84% 13.09%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 5.65 5.20 5.42 6.05 7.89 7.29 6.42 6.79 8.74 6.27 7.07
NOPAT to Interest Expense		 3.59 3.35 3.49 3.87 5.86 4.86 4.72 4.25 5.73 4.37 5.37
EBIT Less CapEx to Interest Expense		 4.93 4.01 4.93 5.36 7.05 5.91 5.66 5.80 7.47 4.42 6.19
NOPAT Less CapEx to Interest Expense		 2.88 2.17 3.00 3.18 5.01 3.48 3.96 3.25 4.46 2.51 4.49
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 2.54% 3.40% 3.39% 3.12% 2.68% 2.53% 2.55% 2.71% 2.97% 3.24% 3.12%
Augmented Payout Ratio		 15.61% 3.40% 3.39% 3.12% 2.68% 2.53% 6.87% 11.45% 12.26% 18.41% 22.63%

Financials Breakdown Chart

Key Financial Trends

GE HealthCare Technologies (NASDAQ: GEHC) showed a mixed but generally stable operating picture in the latest quarter, with solid profitability but some pressure on cash generation and a heavier balance sheet than it had a year ago.

For Q1 2026, revenue rose to $5.13 billion from $4.78 billion in Q1 2025, while gross profit also improved modestly to $1.98 billion. However, operating income slipped to $515 million from $629 million a year earlier because operating expenses climbed faster than revenue. Net income was $411 million, or $0.85 per share, down from $588 million and $1.23 per share in the prior-year quarter.

Cash flow was the biggest weak spot in the quarter. GE HealthCare generated only $290 million of operating cash flow in Q1 2026, down sharply from $250 million in Q1 2025? Actually, the more meaningful comparison is against later 2025 quarters, where operating cash flow was much stronger. The company also spent heavily on acquisitions ($2.30 billion), which drove investing cash outflow to $2.5 billion and left net cash change at a large negative $2.23 billion.

The balance sheet also shifted materially. Cash and equivalents fell to $2.29 billion from $4.03 billion at Q3 2025 and $2.89 billion at year-end 2024, while total debt increased to about $10.13 billion of long-term debt plus $7 million of short-term debt. Total liabilities climbed to $26.23 billion, and equity was $10.68 billion.

Looking at the last four years, GE HealthCare has generally delivered consistent revenue growth and solid profitability, but the trend in operating cash flow has been volatile. The company has also used acquisitions aggressively, which may help growth but has reduced cash and increased leverage.

  • Revenue growth remains intact, with Q1 2026 revenue up year over year to $5.13 billion.
  • Gross profit improved, showing the company still has decent pricing and scale in its business.
  • Net income stayed positive at $411 million in Q1 2026.
  • Cash on hand remains sizable at $2.29 billion, giving GEHC some financial flexibility.
  • Long-term growth investment continues, as R&D spending remains meaningful.
  • EPS was flat at $0.85 in Q1 2026, suggesting earnings are holding up even as the mix shifts.
  • Operating margin is still healthy, but it narrowed as expenses rose faster than revenue.
  • Acquisition activity is significant, which could support long-term growth but makes near-term cash flow lumpier.
  • Operating income declined year over year in Q1 2026 due to higher operating expenses.
  • Cash flow weakened sharply in the latest quarter because of large acquisition spending.

Bottom line: GE HealthCare still looks like a profitable company with a stable top line, but investors should watch the cash flow trend and rising leverage. If management can integrate acquisitions well and restore stronger operating cash generation, the long-term story may remain attractive. For now, the quarter points to a business that is growing, but not without some balance-sheet and cash conversion pressure.

08/04/26 08:57 PM ETAI Generated. May Contain Errors.

GE HealthCare Technologies Financials - Frequently Asked Questions

According to the most recent income statement we have on file, GE HealthCare Technologies' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

GE HealthCare Technologies' net income for the last 5 years looks like this:
  • 2021: $2.29 billion
  • 2022: $1.97 billion
  • 2023: $1.61 billion
  • 2024: $2.05 billion
  • 2025: $2.15 billion
See GE HealthCare Technologies' forecast for analyst expectations on what's next for the company.

GE HealthCare Technologies' total operating income in 2025 was $2.76 billion, based on the following breakdown:
  • Total Gross Profit: $8.25 billion
  • Total Operating Expenses: $5.49 billion

Over the last 4 years, GE HealthCare Technologies' total revenue changed from $17.59 billion in 2021 to $20.63 billion in 2025, a change of 17.3%.

GE HealthCare Technologies' total liabilities were at $26.31 billion at the end of 2025, a 7.7% increase from 2024, and a 46.6% increase since 2022.

In the past 3 years, GE HealthCare Technologies' cash and equivalents has ranged from $1.45 billion in 2022 to $4.51 billion in 2025, and is currently $4.51 billion as of their latest financial filing in 2025.

Over the last 4 years, GE HealthCare Technologies' book value per share changed from 0.00 in 2021 to 22.79 in 2025, a change of 2,278.7%.


Related Companies

Financial statements for NASDAQ:GEHC last updated on 7/29/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
"Second Wave” Hitting Iran Soon? Wall Street Issues Warning
Analysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...
TradeSmith | Sponsoredtc pixel
He knows what's coming this year
An investor famous for predicting the 2008 housing crash has quietly built a $185 million stake in a small Ame...
Behind the Markets | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
1 Stock to Own by July 31st
A scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
70% of the Fortune 100 depend on this mystery AI stock
Seventy percent of the Fortune 100 already rely on one company's AI cybersecurity platform, which combines mor...
The Oxford Club | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel